Efficacy of switching therapy to interferon beta plus ribavirin combination therapy for patients with chronic hepatitis C who discontinues triple therapy with protease inhibitor or dual therapy with Peg-IFN plus RBV combination therapy

Not Applicable

• Conditions: chronic hepatitis C

• Registration Number: JPRN-UMIN000011246
• Lead Sponsor: The department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-08-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with co-infection with hepatitis B virus 2) Patients with co-infection with human immunodeficiency virus 3) Patients with alcoholic liver disorder or autoimmune hepatitis 4) Patients with uncompensated cirrhosis or hepatic failure 5) Patients with multiple organ failure or immunological deficiency 6) Patients with severe depression or past history of psychiatric disorder 7) Patients with chronic renal failure 8) Patients in pregnancy or lactating or patients who expect to become pregnant 9) Patients whose hemoglobin levels are less than 8.5g/dL 10) Patients whose platelet counts are less than 25,000/microL 11) Patients whose neutrophil counts are less than 500 /microL 12) Patients whom investigator disqualified

Study & Design

• Study Type: Interventional
• Study Design: Not specified